Brain Tumor, Primary
Conditions
Keywords
Brain tumor, Glutamate
Brief summary
Gliomas are the most frequent type of primary brain tumors in adults; among them glioblastoma multiforme (GBM) is the most malignant, being associated with the worst prognosis. Glutamate (Glu) is an aminoacid, responsible for essential functions in the Central Nervous System (CNS), acting both as metabolite and neurotransmitter. It is essential for regulating cellular metabolism and developmental synaptogenesis, cellular migration, differentiation and death. Recent scientific evidences have demonstrated alteration in Glu synthesis and signaling being directly involved in GBM growth and invasion
Detailed description
Glu and its scavenger's levels are measurable both in serum and in the cerebral-spinal fluid (CSF), thus making them ideal markers for tumor aggressiveness and disease activity as well as a potential target for new therapeutic approaches. Serum and CSF levels of glutamic oxaloacetic transaminase (GOT1), Glutamate Pyruvate Transaminase (GPT) and glutamate and aspartate levels of a total of 40 patients will be collected. Molecular biology analyses will be conducted and oncological and imaging data will be collected during follow-up in patients enrolled in the present studies. MRI imaging as well as blood sampling will be performed at definite timepoints (baseline and 3, 6 and 9 months follow-up).
Interventions
DIAGNOSTIC_TESTBlood, CSF and tumor samples
Blood, CSF and brain tissue sampling of Glu and Glu regulatory proteins.
Sponsors
IRCCS San Raffaele
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients with a brain lesion suspected for GBM, candidate to gross total tumor resection (GTR), followed by radiotherapy and chemotherapy (concomitant and adjuvant). * Patient able to provide informed consent.
Exclusion criteria
* Age \< 18 years * Liver disease * Severe anemia (Hb \<8mg/dl) * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Baseline characterization of Glutamate scavengers (Glu-sca) levels in serum | Baseline (before surgery) | Serum GOT1 (UI/ml), GPT (UI/ml) |
| Baseline characterization of Glutamate (Glu) levels in serum | Baseline (before surgery) | Serum Glutamate (μM/L) |
| Time changes in Glutamate scavengers (Glu-sca) levels in serum | At 3, 6, 9 months following surgery | Serum GOT1 (UI/ml), GPT (UI/ml) |
| Time changes in Glutamate (Glu) levels in serum | At 3, 6, 9 months following surgery | Serum Glutamate (μM/L) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Characterization of Glutamate scavengers (Glu-sca) levels in cerebrospinal fluid (CSF) | Baseline (before surgery) | CSF levels GOT1 (UI/ml), GPT (UI/ml) |
| Characterization of Glutamate (Glu) levels in cerebrospinal fluid (CSF) | Baseline (before surgery) | CSF levels Glutamate (μM/L) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Association between Glutamate metabolism and Glioblastoma molecular signature | Baseline levels of markers | Association between Glu and Glu-scavengers' levels and molecular patterns of Glioblastoma as described by 2021 WHO classification |
Countries
Italy
Contacts
Primary ContactSincinelli Laura
Outcome results
None listed